John Agwunobi - Bluebird Bio Director
| BLUE Stock | USD 0.92 0.05 5.15% |
Director
Dr. John O. Agwunobi M.D. is an independent Director of the company. Dr. Agwunobi is a Class II director who has served as a member of our Board of Directors since June 2017. Since February 2016, Dr. Agwunobi has served as Chief Health and Nutrition Officer at Herbalife Nutrition Institute, responsible for training, education, science strategy and product development. He has also served as CoPresident of Herbalife since May 2018. Prior to joining Herbalife, Dr. Agwunobi was an independent consultant, advising a number of privatelyheld healthrelated companies, including serving as an advisory board member of Shopko Stores Operating Co., LLC on behalf of the private equity firm Sun Capital Partners. From September 2007 to April 2014, Dr. Agwunobi served as Senior Vice President and President of Health and Wellness for WalMart in the United States where he grew the business and provided insight and advice on the companys health reform position. From December 2005 to September 2007, he served as the Assistant Secretary of Health for the U.S. Department of Health and Human Services, where he was responsible for disease prevention and health promotion. His responsibilities included the oversight of the Centers for Disease Control, National Institute of Health, the U.S. Food and Drug Administration, the office of the U.S. Surgeon General, and numerous other public health offices and programs. Dr. Agwunobi has served on numerous boards, including currently as a director at Magellan Health Inc. and at the U.S. African Development Foundation since 2017.
| Age | 53 |
| Tenure | 7 years |
| Address | 455 Grand Union Boulevard, Somerville, MA, United States, 02145 |
| Phone | 339 499 9300 |
| Web | https://www.bluebirdbio.com |
Bluebird Bio Management Efficiency
The company has return on total asset (ROA) of (0.1501) % which means that it has lost $0.1501 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4781) %, meaning that it created substantial loss on money invested by shareholders. Bluebird Bio's management efficiency ratios could be used to measure how well Bluebird Bio manages its routine affairs as well as how well it operates its assets and liabilities. As of April 25, 2024, Return On Tangible Assets is expected to decline to -0.59. In addition to that, Return On Capital Employed is expected to decline to -0.81. At present, Bluebird Bio's Intangibles To Total Assets are projected to slightly decrease based on the last few years of reporting. The current year's Debt To Assets is expected to grow to 0.48, whereas Non Currrent Assets Other are forecasted to decline to about 33 M.Similar Executives
| Found 5 records | DIRECTOR Age | ||
| Albert Sisto | Terns Pharmaceuticals | 63 | |
| Sarah Payne | Terns Pharmaceuticals | 41 | |
| Bruce Leith | Terns Pharmaceuticals | N/A | |
| Alan Howarth | Terns Pharmaceuticals | 69 | |
| Angus Forrest | Terns Pharmaceuticals | N/A | |
Management Performance
| Return On Equity | -0.48 | ||||
| Return On Asset | -0.15 |
Bluebird bio Leadership Team
Elected by the shareholders, the Bluebird Bio's board of directors comprises two types of representatives: Bluebird Bio inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Bluebird. The board's role is to monitor Bluebird Bio's management team and ensure that shareholders' interests are well served. Bluebird Bio's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Bluebird Bio's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Nick Leschly, CEO and President and Director | ||
| Christopher CPA, Principal CFO | ||
| Elizabeth Pingpank, Director Communications | ||
| James Detore, CFO and Treasurer | ||
| James Mandell, Director | ||
| Jason Cole, Senior Vice President General Counsel, Secretary | ||
| David Davidson, Chief Medical Officer | ||
| Philip Gregory, Chief Scientific Officer | ||
| Jess Rowlands, Head Communications | ||
| Liviu MD, VP Affairs | ||
| Kasra Kasraian, Senior Operations | ||
| John Maraganore, Independent Director | ||
| Susanna High, COO | ||
| Daniel Lynch, Chairman of the Board | ||
| Manisha Pai, Sr. Director, Investor Relations | ||
| Sarah Alspach, Senior Affairs | ||
| Mark Vachon, Director | ||
| Kory Wentworth, Principal Accounting Officer, Vice President - Finance | ||
| Joanne SmithFarrell, Chief Business Officer | ||
| Eric Sullivan, Principal Accounting Officer | ||
| Andrew Obenshain, CEO President | ||
| Mr MD, Chief Officer | ||
| Melissa Bonner, VP Research | ||
| Matt Clawson, IR Contact Officer | ||
| Andrea Walton, Chief Officer | ||
| David Schenkein, Independent Director | ||
| JD Esq, Chief Secretary | ||
| Wendy Dixon, Independent Director | ||
| John Agwunobi, Director | ||
| Richard MD, Chief Officer | ||
| Jeffrey Walsh, COO, Treasurer | ||
| William Baird, CFO | ||
| Alison Finger, Chief Commercial Officer | ||
| Douglas Melton, Director | ||
| Scott Shoemaker, Senior Quality | ||
| Mary Hedley, Director | ||
| Thomas Klima, Chief COO |
Bluebird Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Bluebird Bio a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.48 | ||||
| Return On Asset | -0.15 | ||||
| Operating Margin | (6.84) % | ||||
| Current Valuation | 230.32 M | ||||
| Shares Outstanding | 192.74 M | ||||
| Shares Owned By Insiders | 0.37 % | ||||
| Shares Owned By Institutions | 65.06 % | ||||
| Number Of Shares Shorted | 32.62 M | ||||
| Price To Earning | (19.32) X | ||||
| Price To Book | 0.96 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Bluebird Bio in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Bluebird Bio's short interest history, or implied volatility extrapolated from Bluebird Bio options trading.
Pair Trading with Bluebird Bio
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Bluebird Bio position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Bluebird Bio will appreciate offsetting losses from the drop in the long position's value.Moving together with Bluebird Stock
| 0.61 | VKTX | Viking Therapeutics Buyout Trend | PairCorr |
| 0.65 | ENVB | Enveric Biosciences Financial Report 20th of May 2024 | PairCorr |
Moving against Bluebird Stock
| 0.46 | ACB | Aurora Cannabis Financial Report 12th of June 2024 | PairCorr |
The ability to find closely correlated positions to Bluebird Bio could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Bluebird Bio when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Bluebird Bio - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Bluebird bio to buy it.
The correlation of Bluebird Bio is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Bluebird Bio moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Bluebird bio moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Bluebird Bio can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bluebird bio. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in employment. For information on how to trade Bluebird Stock refer to our How to Trade Bluebird Stock guide.You can also try the Commodity Channel module to use Commodity Channel Index to analyze current equity momentum.
Complementary Tools for Bluebird Stock analysis
When running Bluebird Bio's price analysis, check to measure Bluebird Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bluebird Bio is operating at the current time. Most of Bluebird Bio's value examination focuses on studying past and present price action to predict the probability of Bluebird Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bluebird Bio's price. Additionally, you may evaluate how the addition of Bluebird Bio to your portfolios can decrease your overall portfolio volatility.
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated |
Is Bluebird Bio's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bluebird Bio. If investors know Bluebird will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bluebird Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.63) | Revenue Per Share 0.214 | Quarterly Revenue Growth 173.535 | Return On Assets (0.15) | Return On Equity (0.48) |
The market value of Bluebird bio is measured differently than its book value, which is the value of Bluebird that is recorded on the company's balance sheet. Investors also form their own opinion of Bluebird Bio's value that differs from its market value or its book value, called intrinsic value, which is Bluebird Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bluebird Bio's market value can be influenced by many factors that don't directly affect Bluebird Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bluebird Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Bluebird Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bluebird Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.